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Multiple myeloma (MM) is a currently
incurable neoplasm of terminally differ-
entiated B cells characterized by clonal
expansion of malignant plasma cells in
the bone marrow, development of lytic
bone lesions, and the presence of mono-
clonal immunoglobulin (Ig) in serum
and/or urine. MM is not an uncommon
malignancy, as it accounts for 2% of all
cancer deaths and nearly 20% of deaths
caused by hematological malignancies.
It is often preceded by a premalignant
plasma cell disorder referred to as mono-
clonal gammopathy of undetermined sig-
nificance (MGUS), which progresses to
malignant MM or related disorders at an
approximate rate of 1% per year. MM is
usually confined to the bone marrow
(intramedullary MM), as it is critically
dependent on myeloma cell/bone mar-
row stroma interactions regulating tumor
cell growth, survival, and migration. With
terminal progression to a more aggres-
sive disease phase, myeloma cells can
become independent of the marrow
microenvironment and acquire the ability
to grow at extramedullary sites, such as
blood (“plasma cell leukemia”) or pleural
fluid.
Insights into the molecular patho-
genesis and biology of MM have been
gained mainly from studies on the funda-
mental genetic abnormalities linked with
the transformation and clonal evolution
of malignant plasma cells and from
studies delineating the interactions of
myeloma cells with their bone marrow
microenvironment. Relating the data
from cytogenetics and Ig gene mutation-
al analyses to clinical phases of the dis-
ease has generated a model of a
multistep transformation process from
normal plasma cells through MGUS to
malignant MM (Kuehl and Bergsagel,
2002; Seidl et al., 2003). Apart from the
advances in myeloma genetics, investi-
gations elucidating the complex myelo-
ma-host interactions have recently
culminated in the identification of a
wealth of targets for novel therapeutic
approaches aiming at direct induction of
myeloma cell apoptosis or at overcoming
acquired drug resistance (Hideshima et
al., 2003).
With the recent development of
large-scale DNA microarray technology,
global transcriptional characteristics of
normal, premalignant, and malignant
plasma cells can now be assessed in a
far more comprehensive manner. Gene
expression profiling has already been
used to define the molecular portraits of
the respective plasma/myeloma cells
according to Ig types/light chain sub-
types and in relation to the degree of
transformation (Magrangeas et al., 2003;
Zhan et al., 2002; Davies et al., 2003).
Derived from such studies, novel candi-
date MM disease genes and a gene-
based classification with prognostic
relevance have been suggested (Zhan et
al., 2002). In this issue of Cancer Cell,
Hurt et al. (2004) provide an excellent
example of how this novel technique can
be employed to trace an oncogenic event
and identify its molecular targets.
Profiling gene expression by use of
DNA microarrays in a large panel of
myeloma cell lines, the authors detected
overexpression of c-maf in 50% of all cell
lines studied, a finding confirmed in
myeloma cells purified from a series of
patient bone marrow samples (see
Figure 1). c-maf is the cellular homolog
of v-maf, the transforming gene of the
avian retrovirus AS42, which was first
isolated from a spontaneous fibrosarco-
ma in chicken. It is a member of the basic
leucine zipper transcription factors
belonging to the AP1 superfamily. In lym-
phoid cells, c-maf is a T-helper 2 cells
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Gene expression profiling studies reported by Hurt et al. in this issue of Cancer Cell reveal an unexpectedly frequent over-
expression of c-maf in multiple myeloma and identify molecular targets of c-maf transactivation. The results define c-maf
as a prototype of a class of oncogenes that not only stimulate cell cycle progression, but also promote pathological inter-
actions between tumor and stroma cells.
Figure 1. The onco-
protein c-maf and
its transactivation
targets in multiple
myeloma
Overexpression of c-
maf is a much more
frequent oncogenic
event in multiple
myeloma than was
expected from the
low 5%10% pre-
valence of the 
recurrent t(14;16)
translocation in
which the c-maf
gene locus at
16q23 is dysregulat-
ed under the influ-
ence of enhancer
regions of the IgH
gene at 14q32. Hurt
et al. detected sig-
nificant levels of c-
maf expression in 50% of myeloma cell lines and myeloma cells (MC) purified from patient bone
marrow samples. Transactivation target genes were identified by differential expression profiling of
c-maf positive and negative cell lines as well as MC transduced to overexpress c-maf or trans-
duced with a dominant-negative form of the oncogene. c-maf increases the expression of cyclin
D2, which drives the cells into cycling, and of integrin β7, which promotes adhesion of MC to bone
marrow stroma cells (BMSC). The latter phenomenon is associated with increased secretion of vas-
cular endothelial growth factor (VEGF) known to induce marrow neoangiogenesis and to stimu-
late MC in both an autocrine and a paracrine manner. It remains to be shown whether
c-maf-induced upregulation of the C-C chemokine receptor-1 (CCR1) is part of an autocrine
mechanism in which CCR1 functions as receptor for myeloma-derived MIP-1α.
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transcription factor controlling the
expression of interleukin-4 (IL-4), while
in macrophages it has been shown to
potently activate the expression of IL-4
and IL-10. c-maf is expressed at high lev-
els in myeloma cells carrying the translo-
cation t(14;16) (q32;q23), which results
in fusing Ig heavy chain and c-maf gene
loci (Kuehl and Bergsagel, 2002; Seidl et
al., 2003). However, this primary translo-
cation is present in only 5%–10% of
MMs. Thus, the first important finding
from this paper relates to the molecular
pathogenesis of MM as it identifies c-maf
overexpression as an oncogenic event
occurring in approximately half of all MM
cases, mostly as a result of yet unknown
mechanisms. Confirmation of this unex-
pected frequency will certainly be
required in larger patient cohorts.
The second important aspect is the
identification and functional characteri-
zation of the transactivation targets.
Although unknown to date, it is perhaps
not surprising that c-maf upregulates
cyclin D2, a promoter of cell cycle pro-
gression. In fact, it has been shown that
the vast majority of MM tumors dysregu-
late one or more of the cyclin D1, 2, or 3
genes. More of a surprise is the finding
that the oncoprotein c-maf also increas-
es the expression of integrin β7, an
adhesion molecule that heterodimerizes
with integrin αE to bind to E-cadherin on
the surface of bone marrow stroma cells.
The functional studies performed by 
Hurt et al. confirm that c-maf-regulated
expression of integrin β7 is of pivotal
importance for the adhesion of myeloma
cells to E-cadherin and marrow stroma
cells. Furthermore, the integrin β7-medi-
ated adherence of myeloma to stroma
cells significantly increases the secretion
of vascular endothelial growth factor
(VEGF). VEGF is produced both by
myeloma and marrow stroma cells and is
one of the cytokines known to optimize
the micromilieu for MM tumors via
autocrine and paracrine stimulatory
loops (Dankbar et al., 2000; Podar et al.,
2001). VEGF also possesses potent
angiogenic activity, thus establishing ties
to marrow neoangiogenesis.
Undoubtedly, the discovery of this c-maf-
integrin β7-mediated pathway of myelo-
ma cell adhesion is an important new
piece of information increasing our
understanding of MM pathogenesis in
general and of myeloma-stroma interac-
tions in particular. In addition, these find-
ings on c-maf and its targets are of broad
interest, since they define a class of
oncogenes that enhance mutual interac-
tions between tumor and stroma rather
than rendering the tumor self-sufficient in
growth signals.
What are the clinical implications?
Given the frequency of c-maf overex-
pression in MM, it will be interesting to
explore its prognostic significance both
in terms of survival and incidence of
skeletal events. In addition, the elegant
studies by Hurt et al. suggest c-maf as
an intriguing new therapeutic target in
MM. Indeed, recent developments indi-
cate that oncogene inactivation or target
redirection are promising approaches in
cancer treatment (Felsher, 2003; Steffen
et al., 2003). It should be kept in mind,
however, that c-maf is widely expressed
not only in embryonic but also in adult
tissues. This fact may pose significant
challenges to a c-maf-targeted therapy
for MM.
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